BIIB
Price
$150.71
Change
+$0.33 (+0.22%)
Updated
Mar 10, 04:59 PM (EDT)
Capitalization
31.34B
43 days until earnings call
GRFS
Price
$7.79
Change
-$0.63 (-7.47%)
Updated
Mar 10, 04:59 PM (EDT)
Capitalization
5.48B
51 days until earnings call
Ad is loading...

BIIB vs GRFS

Header iconBIIB vs GRFS Comparison
Open Charts BIIB vs GRFSBanner chart's image
Biogen
Price$150.71
Change+$0.33 (+0.22%)
Volume$53.46K
Capitalization31.34B
Grifols SA
Price$7.79
Change-$0.63 (-7.47%)
Volume$75.3K
Capitalization5.48B
BIIB vs GRFS Comparison Chart
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIIB vs. GRFS commentary
Mar 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a StrongBuy and GRFS is a Hold.

Ad is loading...
COMPARISON
Comparison
Mar 11, 2025
Stock price -- (BIIB: $142.65 vs. GRFS: $8.27)
Brand notoriety: BIIB: Notable vs. GRFS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 188% vs. GRFS: 75%
Market capitalization -- BIIB: $31.34B vs. GRFS: $5.48B
BIIB [@Pharmaceuticals: Major] is valued at $31.34B. GRFS’s [@Pharmaceuticals: Major] market capitalization is $5.48B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whileGRFS’s FA Score has 1 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • GRFS’s FA Score: 1 green, 4 red.
According to our system of comparison, GRFS is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 5 TA indicator(s) are bullish while GRFS’s TA Score has 6 bullish TA indicator(s).

  • BIIB’s TA Score: 5 bullish, 3 bearish.
  • GRFS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both BIIB and GRFS are a good buy in the short-term.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а -0.56% price change this week, while GRFS (@Pharmaceuticals: Major) price change was +12.06% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.88%. For the same industry, the average monthly price growth was +6.28%, and the average quarterly price growth was -4.39%.

Reported Earning Dates

BIIB is expected to report earnings on Apr 23, 2025.

GRFS is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.88% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BIIB($31.3B) has a higher market cap than GRFS($5.48B). GRFS has higher P/E ratio than BIIB: GRFS (68.68) vs BIIB (26.95). GRFS YTD gains are higher at: 11.156 vs. BIIB (-6.716). BIIB has higher annual earnings (EBITDA): 2.04B vs. GRFS (640M). BIIB has more cash in the bank: 1.05B vs. GRFS (544M). BIIB has less debt than GRFS: BIIB (7.34B) vs GRFS (11.1B). BIIB has higher revenues than GRFS: BIIB (9.84B) vs GRFS (6.54B).
BIIBGRFSBIIB / GRFS
Capitalization31.3B5.48B572%
EBITDA2.04B640M318%
Gain YTD-6.71611.156-60%
P/E Ratio26.9568.6839%
Revenue9.84B6.54B151%
Total Cash1.05B544M193%
Total Debt7.34B11.1B66%
FUNDAMENTALS RATINGS
BIIB vs GRFS: Fundamental Ratings
BIIB
GRFS
OUTLOOK RATING
1..100
1019
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
5
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6340
P/E GROWTH RATING
1..100
9694
SEASONALITY SCORE
1..100
5033

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GRFS's Valuation (5) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (93) in the Biotechnology industry. This means that GRFS’s stock grew significantly faster than BIIB’s over the last 12 months.

GRFS's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as BIIB (100) in the Biotechnology industry. This means that GRFS’s stock grew similarly to BIIB’s over the last 12 months.

GRFS's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as BIIB (100) in the Biotechnology industry. This means that GRFS’s stock grew similarly to BIIB’s over the last 12 months.

GRFS's Price Growth Rating (40) in the Pharmaceuticals Major industry is in the same range as BIIB (63) in the Biotechnology industry. This means that GRFS’s stock grew similarly to BIIB’s over the last 12 months.

GRFS's P/E Growth Rating (94) in the Pharmaceuticals Major industry is in the same range as BIIB (96) in the Biotechnology industry. This means that GRFS’s stock grew similarly to BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBGRFS
RSI
ODDS (%)
Bullish Trend 7 days ago
59%
Bearish Trend 7 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 7 days ago
66%
Bearish Trend 7 days ago
70%
Momentum
ODDS (%)
Bullish Trend 7 days ago
56%
Bullish Trend 7 days ago
67%
MACD
ODDS (%)
Bullish Trend 7 days ago
44%
Bullish Trend 7 days ago
67%
TrendWeek
ODDS (%)
Bearish Trend 7 days ago
70%
Bullish Trend 7 days ago
72%
TrendMonth
ODDS (%)
Bearish Trend 7 days ago
70%
Bullish Trend 7 days ago
72%
Advances
ODDS (%)
Bullish Trend 7 days ago
53%
Bullish Trend 8 days ago
70%
Declines
ODDS (%)
Bearish Trend 12 days ago
69%
Bearish Trend 14 days ago
75%
BollingerBands
ODDS (%)
Bullish Trend 7 days ago
46%
Bearish Trend 7 days ago
86%
Aroon
ODDS (%)
Bearish Trend 7 days ago
68%
Bullish Trend 7 days ago
72%
View a ticker or compare two or three
Ad is loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X87222.1950001156.515600
+1.34%
Bitcoin cryptocurrency
GME24.30-0.10
-0.41%
GameStop Corp
AAPL235.93-2.10
-0.88%
Apple
SPY576.86-6.91
-1.18%
SPDR® S&P 500® ETF Trust
TSLA272.04-12.61
-4.43%
Tesla

BIIB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with NVS. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
+0.66%
NVS - BIIB
35%
Loosely correlated
+0.72%
PFE - BIIB
31%
Poorly correlated
-1.90%
AZN - BIIB
23%
Poorly correlated
+1.51%
MRK - BIIB
22%
Poorly correlated
-0.63%
AMGN - BIIB
22%
Poorly correlated
+0.45%
More

GRFS and

Correlation & Price change

A.I.dvisor tells us that GRFS and GIFOF have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GRFS and GIFOF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRFS
1D Price
Change %
GRFS100%
-3.61%
GIFOF - GRFS
26%
Poorly correlated
N/A
BIIB - GRFS
22%
Poorly correlated
+0.66%
AMRN - GRFS
20%
Poorly correlated
+0.02%
ALPMY - GRFS
11%
Poorly correlated
-0.21%
JNJ - GRFS
10%
Poorly correlated
-1.11%
More